Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia - PubMed (original) (raw)
doi: 10.1038/sj.leu.2403263.
V H J van der Velden, T Raff, J Droese, M Ritgen, C Pott, A J Wijkhuijs, N Gökbuget, D Hoelzer, E R van Wering, J J M van Dongen, M Kneba
Affiliations
- PMID: 14961040
- DOI: 10.1038/sj.leu.2403263
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia
M Brüggemann et al. Leukemia. 2004 Apr.
Abstract
Current MRD studies in T-cell acute lymphoblastic leukemia (T-ALL) mainly use T-cell receptor gamma, delta and SIL-TAL1 gene rearrangements as MRD-PCR targets. However, low frequency or limited diversity of these markers restricts the number of evaluable patients, particularly because two markers are recommended for MRD monitoring. Hence, we developed a new strategy implementing the TCR beta (TCRB) locus for MRD quantification. The frequency and characteristics of complete and incomplete TCRB rearrangements were investigated in 53 childhood and 100 adult T-ALL patients using the BIOMED-2 multiplex PCR assay. Clonal rearrangements were identified in 92% both childhood and adult T-ALL (Vbeta-Dbeta-Jbeta rearrangements in 80%, Dbeta-Jbeta rearrangements in 53%). Comparative sequence analysis of 203 TCRB recombinations revealed preferential usage of the 'end-stage' segment Jbeta2.7 in childhood T-ALL (27%), whereas Jbeta2.3 was most frequently involved in adult T-ALL (24%). In complete rearrangements, three downstream Vbeta segments (19-1/20-1/21-1) were preferentially used. Subsequently, a TCRB real-time quantitative PCR assay to quantify MRD with 13 germline Jbeta primer/probe combinations and allele-specific oligonucleotides was developed and applied to 60 clonal TCRB rearrangements. The assay allowed the detection of one leukemic cell within at least 10(4) polyclonal cells in 93% of cases and will be of high value for future MRD studies.
Similar articles
- TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.
van der Velden VH, Brüggemann M, Hoogeveen PG, de Bie M, Hart PG, Raff T, Pfeifer H, Lüschen S, Szczepański T, van Wering ER, Kneba M, van Dongen JJ. van der Velden VH, et al. Leukemia. 2004 Dec;18(12):1971-80. doi: 10.1038/sj.leu.2403505. Leukemia. 2004. PMID: 15470492 - Validation of BIOMED-2 multiplex PCR tubes for detection of TCRB gene rearrangements in T-cell malignancies.
Droese J, Langerak AW, Groenen PJ, Brüggemann M, Neumann P, Wolvers-Tettero IL, van Altena MC, Kneba M, van Dongen JJ. Droese J, et al. Leukemia. 2004 Sep;18(9):1531-8. doi: 10.1038/sj.leu.2403428. Leukemia. 2004. PMID: 15284865 - Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
Szczepański T, Flohr T, van der Velden VH, Bartram CR, van Dongen JJ. Szczepański T, et al. Best Pract Res Clin Haematol. 2002 Mar;15(1):37-57. doi: 10.1053/beha.2002.0184. Best Pract Res Clin Haematol. 2002. PMID: 11987915 Review. - Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. van Dongen JJ, et al. Leukemia. 2003 Dec;17(12):2257-317. doi: 10.1038/sj.leu.2403202. Leukemia. 2003. PMID: 14671650 Review.
Cited by
- Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
van der Velden VHJ, Dombrink I, Alten J, Cazzaniga G, Clappier E, Drandi D, Eckert C, Fronkova E, Hancock J, Kotrova M, Kraemer R, Montonen M, Pfeifer H, Pott C, Raff T, Trautmann H, Cavé H, Schäfer BW, van Dongen JJM, Trka J, Brüggemann M; EuroMRD Consortium. van der Velden VHJ, et al. Leukemia. 2024 Jun;38(6):1315-1322. doi: 10.1038/s41375-024-02272-0. Epub 2024 May 14. Leukemia. 2024. PMID: 38744919 Free PMC article. - Clinical features, laboratory characteristics, and outcome of ETP and TCRA/D aberrations in pediatric patients with T-acute lymphoblastic leukemia.
Ashry MSE, Radwan E, Abdellateif MS, Arafah O, Hassan NM. Ashry MSE, et al. J Egypt Natl Canc Inst. 2023 Jun 12;35(1):17. doi: 10.1186/s43046-023-00176-1. J Egypt Natl Canc Inst. 2023. PMID: 37303010 - Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL.
Dourthe ME, Courtois L, Andrieu GP, Simonin M, Touzart A, Lhermitte L, Petit A, Boissel N, Baruchel A, Asnafi V, Macintyre E. Dourthe ME, et al. Hemasphere. 2023 Mar 17;7(4):e871. doi: 10.1097/HS9.0000000000000871. eCollection 2023 Apr. Hemasphere. 2023. PMID: 36950021 Free PMC article. No abstract available. - Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors.
Iyer A, Hennessey D, Gniadecki R. Iyer A, et al. Blood Adv. 2022 Apr 12;6(7):2334-2345. doi: 10.1182/bloodadvances.2021005884. Blood Adv. 2022. PMID: 35015812 Free PMC article. - Novel clonality assays for T cell lymphoma in cats targeting the T cell receptor beta, T cell receptor delta, and T cell receptor gamma loci.
Radtanakatikanon A, Moore PF, Keller SM, Vernau W. Radtanakatikanon A, et al. J Vet Intern Med. 2021 Nov;35(6):2865-2875. doi: 10.1111/jvim.16288. Epub 2021 Dec 20. J Vet Intern Med. 2021. PMID: 34929760 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources